FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

James Bolognese

Research Profile

Chemicals & Drugs

Procedures

Double-Blind Method

Disorders

Osteoarthritis

Concepts & Ideas

Co-author Network

Publications

TOP 3
Arnold R Gammaitoni; Achilles Alon; James A Bolognese; Bradley S Galer; Mark P Jensen; Steven S Smugar; David J Hewitt
Predicting response to pregabalin from pretreatment pain quality: clinical applications of the pain quality assessment scale.
Mark P Jensen; Steven S Smugar; Achilles Alon; James A Bolognese; Bradley S Galer; Arnold Gammaitoni; David J Hewitt
The pain quality response profile of pregabalin in the treatment of neuropathic pain.
Dale A Schoeller; Achilles Alon; Chan R Beals; James A Bolognese; Steven B Heymsfield; Kenneth C Lasseter; Demetrios Manekas; Lori A Mixson; Gertrude P Noonan; Irene Nunes
Segmental bioimpedance for measuring amlodipine-induced pedal edema: a placebo-controlled study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of James Bolognese (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Arnold R Gammaitoni; Achilles Alon; James A Bolognese; Bradley S Galer; Mark P Jensen; Steven S Smugar; David J Hewitt
Predicting response to pregabalin from pretreatment pain quality: clinical applications of the pain quality assessment scale.
Pain medicine (Malden, Mass.) 2013;14(4):526-32.
2012: Mark P Jensen; Steven S Smugar; Achilles Alon; James A Bolognese; Bradley S Galer; Arnold Gammaitoni; David J Hewitt
The pain quality response profile of pregabalin in the treatment of neuropathic pain.
The Clinical journal of pain 2012;28(8):683-6.
2012: Dale A Schoeller; Achilles Alon; Chan R Beals; James A Bolognese; Steven B Heymsfield; Kenneth C Lasseter; Demetrios Manekas; Lori A Mixson; Gertrude P Noonan; Irene Nunes
Segmental bioimpedance for measuring amlodipine-induced pedal edema: a placebo-controlled study.
Clinical therapeutics 2012;34(3):580-92.
2012: Fabian Chen; Jan de Hoon; Inge De Lepeleire; M Depré; Victor Maridakis; Edward A O'Neill; Waldemar Radziszewski; Kristien van Dyck; Chan Beals; James A Bolognese; Marc Jacquemin
A randomized clinical trial comparing point-of-care platelet function assays and bleeding time in healthy subjects treated with aspirin or clopidogrel.
Platelets 2012;23(4):249-58.
2011: David J Hewitt; Tony W Ho; Bradley Galer; Miroslav Backonja; Paul Markovitz; Arnold Gammaitoni; David Michelson; James A Bolognese; Achilles Alon; Elizabeth Rosenberg; Gary Herman; Hao Wang
Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic pain.
Pain 2011;152(3):514-21.
2010: Rhonda Kaufman; Irene Nunes; James A Bolognese; Deborah L Miller; Dennis Salotti; Jennifer M McCarthy; William B Smith; Gary A Herman; Peter U Feig
Single-dose effects of isosorbide mononitrate alone or in combination with losartan on central blood pressure.
Journal of the American Society of Hypertension : JASH 2010;4(6):311-8.
2010: E Peeva; C R Beals; James A Bolognese; A J Kivitz; L Taber; A Harman; S S Smugar; R W Moskowitz
A walking model to assess the onset of analgesia in osteoarthritis knee pain.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2010;18(5):646-53.
2009: Itay Perlstein; James A Bolognese; Rajesh Krishna; John A Wagner
Evaluation of agile designs in first-in-human (FIH) trials--a simulation study.
The AAPS journal 2009;11(4):653-63.
2006: Sean P Curtis; Amy T Ko; James A Bolognese; Paul F Cavanaugh; Alise S Reicin
Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.
Current medical research and opinion 2006;22(12):2365-74.
2006: Christopher P Cannon; Sean P Curtis; garret fitzgerald; Henry Krum; Amarjot Kaur; James A Bolognese; Alise S Reicin; Claire Bombardier; Michael E Weinblatt; Désirée van der Heijde; Erland Erdmann; Loren Laine
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
Lancet 2006;368(9549):1771-81.
2006: Christopher P Cannon; Sean P Curtis; James A Bolognese; Loren Laine
Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis.
American heart journal 2006;152(2):237-45.
2006: Andreas Reiff; Daniel J Lovell; Janet Van Adelsberg; Maria H B Kiss; Steven Goodman; Manuel Ferrandiz Zavaler; Pei-Yun Chen; James A Bolognese; Paul F Cavanaugh; Alise S Reicin; Edward H Giannini
Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: a 12-week randomized controlled clinical trial with a 52-week open-label extension.
The Journal of rheumatology 2006;33(5):985-95.
2005: Dena R Ramey; Douglas J Watson; Chang Yu; James A Bolognese; Sean P Curtis; Alise S Reicin
The incidence of upper gastrointestinal adverse events in clinical trials of etoricoxib vs. non-selective NSAIDs: an updated combined analysis.
Current medical research and opinion 2005;21(5):715-22.
2004: Douglas J Watson; James A Bolognese; C Yu; David Krupa; S Curtis
Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs.
Current medical research and opinion 2004;20(12):1899-908.
2004: Douglas J Watson; Qinfen Yu; James A Bolognese; Alise S Reicin; Thomas J Simon
The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.
Current medical research and opinion 2004;20(10):1539-48.
2003: James A Bolognese; T J Schnitzer; Elliot W Ehrich
Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement.
Osteoarthritis and cartilage / OARS, Osteoarthritis Research Society 2003;11(7):499-507.
2002: Barry J Gertz; David Krupa; James A Bolognese; Rhoda S Sperling; Alise S Reicin
A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
Current medical research and opinion 2002;18(2):82-91.
2001: James A Bolognese; Elliot W Ehrich; Thomas J Schnitzer
Precision of composite measures of osteoarthritis efficacy in comparison to that of individual endpoints.
The Journal of rheumatology 2001;28(12):2700-4.
2001: Douglas J Watson; SE Harper; PL Zhao; James A Bolognese; Thomas J Simon
Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
MedGenMed : Medscape general medicine 2001;3(4):6.
2001: Lisa DeTora; David Krupa; James A Bolognese; Rhoda S Sperling; Elliot W Ehrich
Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors.
The Journal of rheumatology 2001;28(11):2494-503.
2001: Christopher J Hawkey; L Laine; SE Harper; Hude Quan; James A Bolognese; ER Mortensen
Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials.
Alimentary pharmacology & therapeutics 2001;15(10):1593-601.
2001: Elliot W Ehrich; James A Bolognese; D J Watson; Sheldon X Kong
Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis.
The American journal of managed care 2001;7(6):609-16.
2001: KE Truitt; Rhoda S Sperling; W H Ettinger; M Greenwald; Lisa DeTora; Q Zeng; James A Bolognese; Elliot W Ehrich
A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis.
Aging (Milan, Italy) 2001;13(2):112-21.
2000: Kenneth G Saag; D van der Heijde; C Fisher; A Samara; Lisa DeTora; James A Bolognese; R Sperling; B Daniels
Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group.
Archives of family medicine 2000;9(10):1124-34.
2000: Elliot W Ehrich; G M Davies; Douglas J Watson; James A Bolognese; BC Seidenberg; N Bellamy
Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.
The Journal of rheumatology 2000;27(11):2635-41.
2000: Douglas J Watson; SE Harper; PL Zhao; Hude Quan; James A Bolognese; Thomas J Simon
Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
Archives of internal medicine 2000;160(19):2998-3003.
2000: Richard H Hunt; Barry Bowen; ER Mortensen; Thomas J Simon; Cindy James; A Cagliola; H Quan; James A Bolognese
A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects.
The American journal of medicine 2000;109(3):201-6.
2000: R Day; B Morrison; A Luza; O Castaneda; A Strusberg; M Nahir; K B Helgetveit; B Kress; B Daniels; James A Bolognese; David Krupa; BC Seidenberg; Elliot W Ehrich
A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group.
Archives of internal medicine 2000;160(12):1781-7.
2000: Grant W Cannon; Jacques R Caldwell; P Holt; B McLean; BC Seidenberg; James A Bolognese; Elliot W Ehrich; S Mukhopadhyay; B Daniels
Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group.
Arthritis and rheumatism 2000;43(5):978-87.
2000: C Hawkey; L Laine; T Simon; A Beaulieu; J Maldonado-Cocco; E Acevedo; A Shahane; H Quan; James A Bolognese; E Mortensen
Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group.
Arthritis and rheumatism 2000;43(2):370-7.
1999: M J Langman; D M Jensen; Douglas J Watson; SE Harper; PL Zhao; Hude Quan; James A Bolognese; Thomas J Simon
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
JAMA : the journal of the American Medical Association 1999;282(20):1929-33.
1999: Elliot W Ehrich; Thomas J Schnitzer; Harris H McIlwain; R Levy; F Wolfe; M Weisman; Q Zeng; B Morrison; James A Bolognese; BC Seidenberg; Barry J Gertz
Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. Rofecoxib Osteoarthritis Pilot Study Group.
The Journal of rheumatology 1999;26(11):2438-47.
1999: Thomas J Schnitzer; KE Truitt; R Fleischmann; P Dalgin; J Block; Q Zeng; James A Bolognese; BC Seidenberg; Elliot W Ehrich
The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group.
Clinical therapeutics 1999;21(10):1688-702.
1999: MG Murphy; M A Bach; Diane J Plotkin; James A Bolognese; Jennifer Ng; David Krupa; KA Cerchio; Barry J Gertz
Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1999;14(7):1182-8.
1999: FL Lanza; MF Rack; Thomas J Simon; Hude Quan; James A Bolognese; M E Hoover; F R Wilson; SE Harper
Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen.
Alimentary pharmacology & therapeutics 1999;13(6):761-7.
1996: Cynthia J Girman; C Kolman; C L Liss; James A Bolognese; Bruce Binkowitz; Elizabeth Stoner
Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia. Finasteride Study Group.
The Prostate 1996;29(2):83-90.
1996: P L Zhao; R B Nachbar; James A Bolognese; K Chapman
Two new criteria for choosing sample size in combinatorial chemistry.
Journal of medicinal chemistry 1996;39(2):350-2.
1995: P L Zhao; R Zambias; James A Bolognese; D Boulton; K Chapman
Sample size determination in combinatorial chemistry.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(22):10212-6.
1992: James A Bolognese; R C Kozloff; S C Kunitz; P B Grino; D L Patrick; Elizabeth Stoner
Validation of a symptoms questionnaire for benign prostatic hyperplasia.
The Prostate 1992;21(3):247-54.